Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a global pharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 2002, Amneal develops, manufactures and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products, primarily in the US.

The company operates through three main segments:

Generics: This segment focuses on complex generics, injectables and biosimilars across a broad range of therapeutic areas. Amneal has a large pipeline of generic products in development.

Specialty: This segment has a growing portfolio of branded pharmaceuticals focused on central nervous system and endocrine disorders. Key products include Rytary for Parkinson's disease and Unithroid for hypothyroidism.

AvKARE: This segment distributes pharmaceuticals and other products to US federal government agencies, retail pharmacies and institutional customers.

In 2021, Amneal reported net revenue of USD 2.09 billion and adjusted EBITDA of USD 538 million. The company launched 28 new generic products during the year. As of early 2022, Amneal had approximately 114 generic products with pending regulatory applications and 128 products in development.

Amneal has invested significantly in expanding its manufacturing capabilities, research and development, and commercial infrastructure over the years. The company has tripled its injectables manufacturing capacity recently. Amneal is also building its presence in biosimilars, with over USD 125 million in biosimilar revenues expected in 2024.

The company is led by Co-CEOs and Co-Founders Chirag Patel and Chintu Patel. Amneal employs approximately 7,000 people globally. The company aims to provide high-quality, affordable medicines to patients while creating value for stakeholders through its vertically integrated business model and focus on complex generic and specialty products.

www.amneal.com AMNEAL PHARMACEUTICALS, INC. | 2022 Proxy Statement 18

Required Vote

Our Bylaws provide for a majority vote standard in uncontested elections of directors. Therefore, to be elected at our 2022 annual meeting, which is an uncontested election, each nominee for director must receive the affirmative vote of a majority of the votes cast with respect to such nominee by the holders of the shares of voting common stock voting by remote communication or by proxy at the annual meeting. A majority of the votes cast means that the number of votes cast "for" a nominee must exceed the number of votes cast "against" that nominee.

Recommendation of the Board of Directors

THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" EACH OF THE BOARD OF DIRECTORS' NOMINEES SET FORTH IN PROPOSAL NO. 1.

AMNEAL PHARMACEUTICALS, INC. | 2022 Proxy Statement 25